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INTRODUCTION
Ultrasonography (US) guided-fine-needle aspiration (FNA) 
has been used as the primary diagnostic tool for thyroid nod-
ules, owing to its safety, simplicity, cost-effectiveness, and reli-
ability.1 Since early 2010, several articles have demonstrated 
the safety and tolerability of core-needle biopsy (CNB) for the 
evaluation of thyroid nodules, as well as its diagnostic effica-
cy.2-8 Unlike FNA, which has been validated as a standard diag-
nostic method for over half a century, the value of CNB has not 
yet been fully evaluated for diagnosing thyroid nodules.9-11
The main limitation of FNA is nondiagnostic and indeter-
minate results, corresponding to categories I, III, and IV of 
the Bethesda System for Reporting Thyroid Cytopathology 
(BSRTC).12 To overcome this weakness, some investigators 
have suggested CNB as alternative or complementary diag-
nostic tool for thyroid nodules,5,8,13-16 even though CNB does 
not show superior diagnostic performance to FNA for diagnos-
ing thyroid cancer and poses a higher rate of post-biopsy he-
matoma than FNA.1,17 Many favorable results for CNB have 
been found in studies conducted by experienced radiologists 
and CNB has even been used to diagnose small nodules,5,8,15,16,18 
even micronodules not indicated for FNA in prestigious guide-
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lines.19,20 Considering the thickness of the core needle, the po-
tential risks of CNB might be greater than the expected benefits 
in patients with thyroid nodules, especially in those with small 
nodules, even though CNB shows better diagnostic accuracy 
than FNA. 
The purpose of our study was to compare the diagnostic per-
formances of FNA and CNB performed simultaneously at 
outside clinics for thyroid nodules according to nodule size. 
MATERIALS AND METHODS
Our Yonsei University Institutional Review Board approved 
this retrospective study (IRB No. 4-2019-0745), and the re-
quirement for informed consent was waived for review of im-
ages and medical records.
Study population
Between July 2012 and May 2019, patients who underwent 
both FNA and CNB for a thyroid nodule from one of 71 outside 
clinics were included. Among these patients, 320 patients who 
underwent surgery in our institution were finally included in 
our study. The median age of patients was 42 years (range, 19–
74 years), and the median size of nodules was 10 mm (range, 
3–62 mm). There were 250 female patients and 70 male pa-
tients (Table 1). 
Staging US and cytopathology reports
Preoperative staging US was performed by one of 33 radiolo-
gists with 1–22 years of experience in thyroid imaging. The ra-
diologists prospectively recorded the size and US features of 
thyroid nodules that had undergone FNA or CNB at outside 
clinics into our institutional database. The recorded US features 
were composition, echogenicity, margin, calcifications, and 
shape.21
In our institution, all cytopathologic slides from outside clin-
ics were reviewed by one of the 15 cytopathologists in our in-
stitution according to the review schedule before surgery. Cy-
tology reports were based on the six categories of the BSRTC.12 
The CNB pathologic reports were categorized into the same six 
categories of the Bethesda System according to a recently pro-
posed guideline by a radiologist (K.J.Y.), because the diagnos-
tic categories of CNB have yet to be standardized for thyroid 
nodules (Fig. 1).22
Data and statistical analysis 
Surgical pathologic diagnosis was defined as the standard ref-
erence. One nodule was interpreted as “malignancy” on FNA 
and “suspicious for malignancy (SUSP)” on CNB, although no 
residual cancer was noted in the surgical specimen. In this 
study, the nodule was considered as a cancer because central 
lymph node metastases were seen on the pathologic samples. 
We compared demographics between benign and malignant 
nodules, using the chi-square or Fisher’s exact test for categori-
cal variables and the Mann-Whitney U test for continuous vari-
ables. 
To calculate the diagnostic performances of both FNA and 
CNB, we defined various combinations of test-negatives and 
test-positives according to the Bethesda categories to assess 
malignancy and designated these combinations as Criteria 1 
Table 1. Demographic Data of 320 Nodules in 320 Patients
Total (n=320) Benign (n=41) Malignant (n=279 ) p value
Median age (yr) 42 (19–74) 39 (22–68) 42 (19–74) 0.783
Median nodule size (mm) 10 (3–62) 23 (5–62) 10 (3–47) <0.001
Male sex 70 (21.9) 11 (26.8) 59 (21.2) 0.411
FNA results <0.001
Nondiagnostic 23 (7.2) 8 (19.5) 15 (5.4)
Benign 18 (5.6) 12 (29.3) 6 (2.2)
AUS/FLUS 75 (23.4) 18 (43.9) 57 (20.4)
FN/SFN 2 (0.6) 2 (4.9) 0 (0)
SUSP 88 (27.5) 0 (0) 88 (31.5)
Malignancy 114 (35.6) 1 (2.4) 113 (40.5)
CNB results <0.001
Nondiagnostic 18 (5.6) 2 (4.9) 16 (5.7)
Benign 8 (2.5) 1 (2.4) 7 (2.5)
AUS/FLUS 59 (18.4) 23 (56.1) 36 (12.9)
FN/SFN 18 (5.6) 15 (36.6) 3 (1.1)
SUSP 32 (10.0) 0 (0) 32 (11.5)
Malignancy 185 (57.8) 0 (0) 185 (66.3)
FNA, fine-needle aspiration; CNB, core-needle biopsy; AUS/FLUS, atypia of undetermined significance or follicular lesion of undetermined significance; FN/SFN, 
follicular neoplasm or suspicious for follicular neoplasm; SUSP, suspicious for malignancy.
Values are number (%) or number (range).
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to 5 (Table 2).4,8,14,16,23,24 In Criteria 1, “benign” was considered 
as test-negative, and “SUSP” and “malignancy” were consid-
ered as test-positive. In Criteria 2, “benign” was considered as 
test-negative, and “follicular neoplasm or suspicious for follic-
ular neoplasm (FN/SFN),” “SUSP,” and “malignancy” were 
considered as test-positive. In Criteria 3, “nondiagnostic,” “be-
nign,” and “atypia of undetermined significance or follicular 
lesion of undetermined significance (AUS/FLUS)” were con-
sidered as test-negative, and the remaining categories were 
considered as test-positive. In Criteria 4, “SUSP” and “malig-
nancy” were considered as test-positive, and the remaining 
categories were considered as test-negative. In Criteria 5, “ma-
lignancy” was considered as test-positive, and the remaining 
categories were considered as test-negative. We calculated the 
sensitivites, specificities, accuracies, positive predictive values 
(PPVs), negative predictive values (NPVs), and areas under 
the receiver operating characteristic curve (AUCs) along with 
95% confidence intervals (CIs) of FNA and CNB to diagnose 
thyroid malignancy. These variables were compared using the 
generalized estimated equation and the AUCs using the De-
long method. All diagnostic performances of FNA and CNB 
were calculated and compared separately for all nodules, nod-
ules ≥10 mm, and nodules ≥20 mm, respectively. All analyses 
were performed with SPSS version 25 (IBM Corp., Armonk, 
NY, USA) and SAS (version 9.4, SAS Institute Inc., Cary, NC, 
USA). A p value of less than 0.05 was considered to indicate a 
significant difference. 
RESULTS
Baseline clinicopathological characteristics 
There were 279 malignant nodules in 279 patients and 41 be-
nign nodules in 41 patients (Tables 1 and 3). The median age 
(42 years, range; 19–74 years) of the patients with malignant 
nodules was not significantly different from that (39 years, 
range; 22–68 years) of patients with benign nodules. The me-
dian size of benign nodules was 23 mm, which was significant-
ly larger than that of malignant nodules (10 mm) (p<0.001). 
There was no statistical association between malignancy risk 
and gender. Significant differences were evident between be-
nign and malignant nodules for the FNA and CNB results (p< 
0.001). 
The proportions of the “benign” and “SUSP” categories were 
higher in FNA than in CNB (p=0.049 and p<0.001, respective-
ly). In contrast, the proportions of the “FN/SFN” and “malignan-
cy” categories were higher in CNB than in FNA (p<0.001).
Diagnostic performances of FNA and CNB 
Table 4 demonstrates the diagnostic performances of FNA and 
CNB according to nodule size using Criteria 1–5. 
When applying Criteria 1 and 2, diagnostic performance 
mostly did not differ between FNA and CNB in all nodules, 
except for NPV, which was better for FNA FNA (66.7%; 95% CI: 
44.9–88.4 for Criteria 1 and 48.8%; 95% CI: 33.5–64.1 for Crite-
ria 2) than for CNB (12.5%; 95% CI: 0–35.4 for Criteria 1 and 
11.5%; 95% CI: 0–23.8 for Criteria 2) (p<0.001). When applying 
Criteria 3, specificity and PPV were higher for FNA (92.7%; 95% 
CI: 84.7–100 for specificity and 98.5%; 95% CI: 96.9–100 for 
Table 2. Diagnostic Criteria
Criteria Test-negative Test-positive
Criteria 11,23,24 Benign SUSP, malignancy
Criteria 21,24 Benign
FN/SFN, SUSP, 
  malignancy
Criteria 31,8,24 Nondiagnostic, benign, AUS/FLUS
FN/SFN, SUSP, 
  malignancy
Criteria 41,4,14
Nondiagnostic, benign, AUS/FLUS, 
  FN/SFN
SUSP, malignancy
Criteria 58,16
Nondiagnostic, benign, AUS/FLUS, 
  FN/SFN, SUSP
Malignancy
AUS/FLUS, atypia of undetermined significance or follicular lesion of undeter-
mined significance; FN/SFN, follicular neoplasm or suspicious for follicular 
neoplasm; SUSP, suspicious for malignancy.
Fig. 1. US images of a 35-year-old female with a papillary thyroid carcinoma, conventional type, which was diagnosed as “malignancy” on fine-needle as-
piration and “nondiagnostic” on core-needle biopsy detected at an outside clinic. A 1.3-cm solid hypoechoic nodule (arrows) with microlobulated margins 
and mixed calcifications was seen on the axial (A) and longitudinal (B) scans of US. US, ultrasonography.
A B
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PPV) than for CNB (63.4%; 95% CI: 48.7–78.2 for specificity and 
93.6%; 95% CI: 90.5–96.7 for PPV) (p<0.001 and p=0.003, re-
spectively). Accuracy and NPV were not statistically different 
between FNA and CNB. The sensitivity (78.9%; 95% CI: 74.1–
83.6) of CNB was higher than that (72%; 95% CI: 66.8–77.3) of 
FNA (p=0.036). When applying Criteria 4, the diagnostic per-
formance of FNA was similar to that of CNB. When applying 
Criteria 5, sensitivity, accuracy, and NPV were significantly 
higher for CNB than FNA. 
In nodules ≥1 cm, FNA showed superior diagnostic perfor-
mance over CNB in terms of NPV with Criteria 1 and 2 and 
specificity and PPV with Criteria 3. The other measures of di-
agnostic performance were not different between FNA and 
CNB when Criteria 1–3 were used. When Criteria 4 was ap-
plied, none of the diagnostic performance measures of FNA 
significantly differed from CNB. When applying Criteria 5, 
sensitivity, accuracy, and NPV were significantly higher for 
CNB than for FNA. 
In nodules ≥2 cm, FNA showed superior diagnostic perfor-
mance over CNB in terms of NPV with Criteria 1 and 2 and 
specificity and PPV with Criteria 3. The other measures of di-
agnostic performance were not different between FNA and 
CNB when Criteria 1–3 were used. When Criteria 4 and 5 were 
applied, the diagnostic performance of FNA did not statisti-
cally differ from that of CNB. 
Table 3. Final Surgical Diagnosis According to FNA and CNB Results
FNA CNB
Final diagnosis
Malignant (n=279) Benign (n=41)
Nondiagnostic (23) Nondiagnostic (1) AH (1)
Benign (1) PTC FV (1)
AUS/FLUS (9) PTC conv (3), FC MI (1) FA (2), AH (3)
FN/SFN (2) AH (1), HCA (1)
SUSP (1) PTC FV (1)
Malignancy (9) PTC conv (7), PTC FV (1), anaplastic carcinoma (1)
Benign (18) AUS/FLUS (6) AH (3), FA (1), HCA (1), NIFTP (1)
FN/SFN (7) FC MI (1) AH (1), FA (5)
SUSP (1) PTC conv (1)
Malignancy (4) PTC conv (3), PTC FV (1)
AUS/FLUS (75) Nondiagnostic (8) PTC conv (4), PTC FV (3) FA (1)
Benign (1) AH (1)
AUS/FLUS (25) PTC conv (5), PTC FV (5), FC MI (5) AH (5), FA (4), SAT (1)
FN/SFN (8) FC MI (1), PTC FV (1) AH (1), FA (4), HCA (1)
SUSP (8) PTC conv (8)
Malignancy (25) PTC conv (22), PTC FV (3)
FN/SFN (2) AUS/FLUS (1) FA (1)
FN/SFN (1) AH (1)
SUSP (88) Nondiagnostic (7) PTC conv (7)
Benign (3) PTC conv (3)
AUS/FLUS (8) PTC conv (6), PTC FV (2)
SUSP (11) PTC conv (9), PTC FV (2)
Malignancy (59) PTC conv (56), PTC FV (2), MTC (1)
Malignancy (114) Nondiagnostic (2) PTC conv (2)
Benign (3) PTC conv (3)
AUS/FLUS (10) PTC conv (9) AH (1)
SUSP (11) PTC conv (9), PTC FV (1), no residual carcinoma (1)*
Malignancy (88) PTC conv (86), PTC FV (1), PTC solid variant (1)
FNA, fine-needle aspiration; CNB, core-needle biopsy; AUS/FLUS, atypia of undetermined significance or follicular lesion of undetermined significance, FN/SFN, 
follicular neoplasm or suspicious for follicular neoplasm; AH, adenomatous hyperplasia; FA, follicular adenoma; HCA, Hürthle cell adenoma; MTC, medullary 
thyroid carcinoma; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PTC FV, papillary thyroid carcinoma, follicular variant; PTC 
conv, papillary thyroid carcinoma, conventional; SAT, subacute granulomatous thyroiditis; SUSP, suspicious for malignancy; FC MI, follicular carcinoma, minimally 
invasive.
Data in parentheses are number of nodules.
*One nodule was “malignancy” on FNA and “SUSP” on CNB. On the pathologic sample, there was no residual cancer. However, central lymph node metastases 
were seen on the pathologic samples. Therefore, the nodule was considered as a cancer in this study. 
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DISCUSSION
In this study, the diagnostic performance of FNA was mostly 
the same as that of CNB, regardless of nodule size, except for 
NPV, which was better for FNA than for CNB when applying 
Criteria 1 and 2. When applying Criteria 3, the specificity and 
PPV of FNA were superior to CNB regardless of size. When ap-
plying Criteria 4, diagnostic performance did not differ between 
FNA and CNB, regardless of size, unlike the results of a previ-
ous study that found CNB to have higher sensitivity and accu-
racy than FNA.4 After applying Criteria 5, diagnostic perfor-
mance did not differ between FNA and CNB in nodules ≥2 cm 
(not small nodules). However, in nodules ≥1 cm and all nod-
ules, the sensitivity, accuracy, and NPV of CNB were better than 
those of FNA, findings which were similar to those of a pub-
lished study.8
Several investigators have suggested that CNB is superior to 
FNA and that it may be a potential first-line diagnostic tool.4,8,14,16 
In these studies, the “nondiagnostic,” “benign,” “AUS/FLUS,” 
and “FN/SFN” categories were regarded as test-negative, and 
the “nondiagnostic,” “benign,” “AUS/FLUS,” and “FN/SFN” cat-
egories with and without the “SUSP” category were regarded 
as test-positive, which were the same designations used for Cri-
teria 4 and 5, respectively, in our study.4,8,14,16 In other studies, 
the diagnostic performance of FNA was calculated by regard-
ing the “benign” category with and without the “nondiagnos-
tic” category as test-negative (Criteria 1 and 2 in our study, 
respectively) or by regarding the combination of the “nondiag-
nostic,” “benign,” and “AUS/FLUS” categories as test-negative 
(Criteria 3 in our study).23,24 According to BSRTC, the risk of ma-
lignancy was 15–30% and 60–75% for thyroid nodules catego-
rized as “FN/SFN” and “SUSP,” respectively.12 Considering that 
“FN/SFN” and “SUSP” nodules have relatively high risks of ma-
lignancy and are recommended for surgery according to the 
BSRTC, a nodule with the above cytologic categories should 
not be considered as test-negative when calculating the diag-
nostic performances of FNA or CNB (Criteria 4 and 5). Based 
on the results of our study, we need to reconsider previous re-
search that found CNB to be more reliable or accurate than 
FNA, and CNB cannot be considered as a first-line diagnostic 
tool for diagnosing thyroid nodules without more supportive 
evidence. 
To obtain tissue samples without damage to the adjacent tis-
sues, it is important to visualize the entire needle. Therefore, the 
core needle should be positioned parallel to the transducer. 
Unlike the core needle in CNB, the fine needle in FNA can be 
inserted in various directions with to-and-fro motions to ob-
tain cells from different sites of the thyroid nodule for repre-
sentative sampling.25 Differences in the methods of FNA and 
CNB may explain their different diagnostic performances.
Percutaneous CNB is a useful diagnostic tool for diagnosing 
soft tissue lesions, especially breast lesions, and surgical exci-
sion biopsies can be avoided with its use.26,27 CNB has also been Ta
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reported as a safe tool for diagnosing thyroid nodules with low 
complication rates.2 However, as the core needle is thicker than 
the fine needle, it might cause more severe and permanent 
damage to the adjacent major organs than the thinner fine 
needle (Supplementary Figs. 1 and 2, only online). 
This study has several limitations. First, patient selection bias 
exists because we included patients who underwent both FNA 
and CNB before surgery. Second, we could not evaluate the 
experience levels of the physicians who performed both FNA 
and CNB as these procedures took place at outside clinics. 
However, the results of this study can reflect the real clinical 
value of FNA and CNB. Third, the results of the first procedure 
may have affected the next procedure. Commonly, FNA is per-
formed before CNB even when they are both performed dur-
ing the same session/visit. Therefore, the results of CNB can 
be influenced by the procedures undertaken for FNA. Fourth, 
although our findings indicate that CNB cannot be a main di-
agnostic tool for thyroid nodules, it can still play a role in diag-
nosing thyroid lymphoma, anaplastic carcinoma, and metas-
tasis from other organs.28-30 In this study, we were unable to 
evaluate the selective indications of CNB. Finally, we did not 
assess diagnostic performance for predicting neoplasm be-
cause there were only a small number of FNs in this study.
In conclusion, CNB did not show superior diagnostic perfor-
mance to FNA for diagnosing thyroid nodules.
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